AI assistant
HAEMONETICS CORP — Director's Dealing 2021
May 20, 2021
31565_dirs_2021-05-20_91fa5ab4-d558-41d5-b921-3ba5aa219e7f.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: HAEMONETICS CORP (HAE)
CIK: 0000313143
Period of Report: 2021-05-18
Reporting Person: Lingamneni Anila (EVP, Chief Technology Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-05-18 | Common Stock | A | 3535 | — | Acquired | 7224 | Direct |
| 2021-05-18 | Common Stock | A | 7070 | — | Acquired | 14294 | Direct |
| 2021-05-19 | Common Stock | S | 92 | $55.19 | Disposed | 14202 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2021-05-18 | Non-qualified Stock Option (Right to Buy) | $56.57 | A | 9564 | Acquired | 2028-05-18 | Common Stock (9564) | Direct |
Footnotes
F1: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan. The RSUs vest in annual increments of 25% beginning on the first anniversary of the date of grant.
F2: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.
F3: This number includes unvested RSUs previously reported as well as 245 shares acquired by the reporting person under the Issuer's 2007 Employee Stock Purchase Plan (as amended) on April 30, 2021.
F4: The securities awarded are in the form of RSUs issued pursuant to the Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan. The RSUs vest in annual increments of 50% beginning on the first anniversary of the date of grant.
F5: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain RSUs previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2019 Long Term Incentive Compensation Plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
F6: Option vests in annual increments of 25% beginning on the first anniversary of the date of grant.